RetinalGenix Technologies (RTGN) Liabilities and Shareholders Equity (2020 - 2026)
RetinalGenix Technologies (RTGN) posted Liabilities and Shareholders Equity of $5805.0 for Q1 2026, down 72.41% sequentially from $21041.0 in Q4 2025, and down 51.35% YoY from $11931.0 in Q1 2025.
RetinalGenix Technologies (RTGN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
RetinalGenix Technologies has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $5805.0 in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 51.35% year-over-year to $5805.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42235.0 (down 79.17% YoY) and the FY2025 annual result came in at $21041.0, up 40.78% from the prior year.
- Liabilities and Shareholders Equity eased to $5805.0 in Q1 2026 per RTGN's latest filing, from $21041.0 in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $88854.0 in Q3 2024 and troughed at $27.0 in Q2 2022.
- A 5-year average of $18381.9 and a median of $7001.0 in 2025 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 94.25% in 2023, then jumped 39390.67% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $294.0 in 2022, then sank by 46.94% to $156.0 in 2023, then soared by 9480.77% to $14946.0 in 2024, then jumped by 40.78% to $21041.0 in 2025, then slumped by 72.41% to $5805.0 in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5805.0, $21041.0, and $7001.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 5,805.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,805.00 |
| Dec 31, 2025 | 21,041.00 |
| Sep 30, 2025 | 7,001.00 |
| Jun 30, 2025 | 8,388.00 |
| Mar 31, 2025 | 11,931.00 |
| Dec 31, 2024 | 14,946.00 |
| Sep 30, 2024 | 88,854.00 |
| Jun 30, 2024 | 87,019.00 |
| Mar 31, 2024 | 50,517.00 |
| Dec 31, 2023 | 156.00 |
| Sep 30, 2023 | 225.00 |
| Jun 30, 2023 | 2,119.00 |
| Mar 31, 2023 | 7,701.00 |
| Dec 31, 2022 | 294.00 |
| Sep 30, 2022 | 3,914.00 |
| Jun 30, 2022 | 27.00 |
| Mar 31, 2022 | 2,555.00 |
| Dec 31, 2021 | 4,947.00 |
| Sep 30, 2021 | 36,578.00 |
| Dec 31, 2020 | 61,075.00 |